This clinical trial investigates a new treatment for patients with liver cirrhosis who have experienced complications of their disease. The study focuses on patients whose liver condition has worsened, leading to complications such as fluid buildup in the abdomen, mental confusion, or bleeding. The main treatment being tested is called RTX001, which consists of specially modified white blood cells (macrophages) that are taken from the patient’s own body and then given back through an infusion into the vein. During the treatment, patients will also receive filgrastim (Neupogen), a medication that helps produce more white blood cells.

The purpose of this research is to determine if RTX001 is safe to use and how well patients tolerate the treatment. The study will involve collecting cells from the patient’s blood through a procedure called leukapheresis, processing these cells to create RTX001, and then giving the processed cells back to the patient through an intravenous infusion. Researchers will monitor patients for any side effects and track how their liver condition changes after receiving the treatment.

This is an early-phase study that will help researchers understand how this new cell therapy might work for patients with severe liver disease. The treatment approach is considered experimental, as it uses modified cells from the patient’s own immune system to potentially help improve liver function. Throughout the study, patients will have regular check-ups to monitor their health and assess how they respond to the treatment.